Clinical Microbiology and Infection

Papers
(The H4-Index of Clinical Microbiology and Infection is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Interpretation of SARS-CoV-2 replication according to RT-PCR crossing threshold value715
Has the COVID-19 pandemic wiped out the seasonality of outpatient antibiotic use and influenza activity? A time-series analysis from 2014 to 2021592
COVID-19 in special populations400
Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing399
Re: Diagnostic limitations and challenges in current clinical guidelines and potential application of metagenomic sequencing to manage pulmonary invasive fungal infections in patients with haematologi390
Primary antifungal prophylaxis after haematopoietic stem cell transplantation: will the search for perfection become the enemy of good?302
Corrigendum to “Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations” [Clin Microbiol and Infect 26 (1) (2020) 60–70]271
Re: ‘The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 20246
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study189
Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia178
Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness163
Outside Front Cover159
Should multiplex PCR testing be integrated into antimicrobial stewardship programs for paediatric community-acquired pneumonia in the emergency department?156
Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)155
‘Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward’ – author's response141
Exploring the limits of interferon-γ releasing assay screening in large-scale populations139
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern137
Pathogen and host determinants of extrapulmonary tuberculosis among 1035 patients in Frankfurt am Main, Germany, 2008–2023132
The diagnostic value of serum Borrelia burgdorferi antibodies and seroconversion after Lyme neuroborreliosis, a nationwide observational study125
What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review112
How to: Diagnose inborn errors of intrinsic and innate immunity to viral, bacterial, mycobacterial, and fungal infections110
Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain108
Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays106
Acquired fluconazole resistance and genetic clustering in Diutina (Candida) catenulata from clinical samples105
Mycotic aneurysm of the infrarenal abdominal aorta infected by Mycoplasma hyorhinis diagnosed with direct 16S ribosomal DNA sequencing100
Re: what is the role of epidemiological investigations in human Campylobacter outbreaks in the One Health and whole-genome sequencing era in Denmark?100
Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models93
Re: Compromised access to antibiotics: addressing paediatric challenges in availability and responsible use91
Acute cough in outpatients: what causes it, how long does it last, and how severe is it for different viruses and bacteria?91
Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples85
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments84
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay84
Large language models (LLMs) for antibiotic prescribing — moving the needle from ‘parlor trick’ to practical tool80
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab79
Post-acute COVID-19 syndrome: a new tsunami requiring a universal case definition76
European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists)76
Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation75
Non-biomedical factors affecting antibiotic use in the community: a mixed-methods systematic review and meta-analysis73
Re: ‘Association between pertactin-producing Bordetella pertussis and fulminant pertussis in infants: a multicentre study in France, 2008–2019’ by Leroux et al.73
PRAISE: providing a roadmap for automated infection surveillance in Europe71
Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis67
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate67
Antimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections66
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review64
Re: ‘Heightened incidence of adverse events associated with a live attenuated varicella vaccine strain that lacks critical genetic polymorphisms in ORF62’ by Kim et al.64
Oral step-down with β-lactams for uncomplicated Enterobacterales bacteraemia62
Effect of antiseptic bathing with chlorhexidine or octenidine on central line–associated bloodstream infections in intensive care patients: a cluster-randomized controlled trial61
Fulminant cytokine release syndrome in a paediatric patient with refractory Epstein–Barr virus-associated haemophagocytic lymphohistiocytosis receiving nivolumab treatment59
A chronic infectious bladder stone causing an obstructive emphysematous cystitis59
Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia59
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies58
Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients57
Evaluating stratified T-SPOT.TB results for diagnostic accuracy in tuberculosis disease: a retrospective cohort study with sensitivities, specificities, and predictive values57
Comparison of β-D-Glucan levels between Candida auris and other Candida species at the time of candidaemia: a retrospective study56
Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up56
Comparing large language models for antibiotic prescribing in different clinical scenarios: which performs better?56
0.14188098907471